MRXBR02 Cardiac Fibrosis (Heart Failure with preserved Ejection Fraction or ‘HFpEF’)
HFpEF is a study designed to evaluate the cardioprotective effects of Ananda’s MRX1 drug candidate in a preclinical HFpEF model. The first part of the study was completed in June 2024.
About HFpEF and its treatment
Cardiac fibrosis is a condition characterised by the thickening and stiffening of the heart tissue, often leading to impaired heart function. HFpEF, accounting for 50% of heart failure cases, presents as clinical heart failure symptoms with a normal ejection fraction. This condition’s incidence is rising with the aging population and the increasing prevalence of comorbidities, making it a critical unmet need in cardiology.
HFpEF is a type of heart failure where the heart muscle contracts normally, but the ventricles do not relax as they should during diastole. This condition leads to symptoms of heart failure despite a normal ejection fraction, which measures the percentage of blood leaving the heart each time it contracts.
There are currently no specific treatments for HFpEF with proven efficacy.
Trial Team:
Nadine Godsman, PhD. Research Fellow at Robert Gordon University and Sarah Walsh, PhD. Senior Research Fellow at Robert Gordon University.